Identity
Hexarelin is a synthetic growth-hormone-releasing hexapeptide.
Selected study only; not a complete clinical review.
Peptide library
Hexarelin
Your guide to this compound.
Mechanism illustrationEnlarge
Evidence in perspective
The small rising-dose IV study tests acute endocrine response. It cannot establish a favorable balance of sustained functional benefit and endocrine harms in healthy users.
About this assessment
Existing source snapshot critically reassessed.
Based on the selected source scope described in this profile, often an indexed abstract. Full methods and clinician sign-off remain pending; no systematic-review claim.
Editorial assessment · 2026-09-07
Who was studied
12 adult men; placebo-controlled rising-dose intravenous study.
What the sources found
Intravenous doses produced a growth-hormone response. This was a physiological experiment, not a muscle-growth treatment trial.
Regulatory scope
Current authorization for the exact product and jurisdiction was not independently checked in this snapshot. A clinical trial is not marketing authorization.
What remains unknown
Selected indexed primary-study abstract reviewed. Full methods, bias, all safety outcomes, product stability, current jurisdictional authorization and a comprehensive literature search remain outstanding. This is not a complete clinical review.
How it works
Hexarelin is a synthetic growth-hormone-releasing hexapeptide.
The study-specific findings below distinguish biological activity from demonstrated treatment benefit.
Limited clinical evidence
The catalog describes a limited clinical evidence base. Small or uncontrolled studies may not separate treatment effects from chance, placebo effects or bias.
Reported adverse effects
- The indexed abstract is truncated; full safety extraction remains outstanding.
Selected study only; not a complete clinical review.
Contraindications
- A complete contraindication and interaction review remains outstanding.
Limited clinical evidence
The catalog describes a limited clinical evidence base. Small or uncontrolled studies may not separate treatment effects from chance, placebo effects or bias.
Sources used for this snapshot
Claim-by-claim evidence
Benefits
Intravenous doses produced a growth-hormone response. This was a physiological experiment, not a muscle-growth treatment trial.
Selected study only; not a complete clinical review.
Adverseeffects
The indexed abstract is truncated; full safety extraction remains outstanding.
Selected study only; not a complete clinical review.
Pharmacokinetics
The cited study reports roughly 55 minutes for the growth-hormone response, not hexarelin elimination. A human hexarelin half-life was not established by this abstract.
Selected study only; not a complete clinical review.
References
Growth hormone-releasing activity of hexarelin in humans. A dose-response study. 1994.
PMID: 7957536
Catalog review date: Sep 7, 2026. This date alone does not establish independent clinical review.